Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading INmune Bio’s SEC documents often means decoding dense science, shifting clinical timelines, and dozens of risk factors spread across 200-plus pages. If you are hunting for R&D burn rates or trying to spot when executives file Form 4 insider transactions, the traditional EDGAR interface can feel overwhelming.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn every filing—from the annual report 10-K to the latest 8-K material event—into plain English. Real-time alerts ensure you see INmune Bio Form 4 insider transactions in real-time the moment they hit the tape, while side-by-side views compare sequential quarters to highlight trial-related spending shifts inside the INmune Bio quarterly earnings report 10-Q filing.
Wondering what to focus on? Investors often use our tools to:
- Track executive stock transactions and cash raises noted in INmune Bio executive stock transactions Form 4
- Analyze pipeline disclosures through an INmune Bio earnings report filing analysis
- Review board pay details in the INmune Bio proxy statement executive compensation
- Monitor trial data releases via INmune Bio 8-K material events explained
Every filing type—S-3 shelves for future capital, S-8 equity plans, or DEF 14A proxy statements—is captured automatically and paired with concise AI commentary so you spend minutes, not hours, understanding INmune Bio SEC documents with AI. If you need the full text, it is one click away, but our synthesized highlights pinpoint the sections that drive valuation for a clinical-stage biotech whose success hinges on data and capital.
Stop searching multiple sources: get INmune Bio SEC filings explained simply with Stock Titan’s complete, constantly updated archive.
Highbridge Capital Management, LLC reported beneficial ownership of 1,454,400 shares of Inmune Bio, Inc. common stock that are issuable upon exercise of warrants. That amount represents 5.2% of the company's outstanding common stock on a base of 26,585,258 shares as stated in the issuer's prospectus, and the filing clarifies these shares are held by Highbridge-managed funds. The filing identifies Highbridge as a Delaware investment adviser and reports sole voting and dispositive power over the 1,454,400 shares. The statement asserts the securities were acquired in the ordinary course of business and not for the purpose of influencing control.
INmune Bio Inc. disclosure shows two reporting persons—CVI Investments, Inc. and its investment manager Heights Capital Management, Inc.—beneficially hold 1,396,279 shares represented by warrants. Those shares equal 4.9% of the outstanding common stock based on 26,585,258 shares reported outstanding as of June 30, 2025. The warrants include an anti-exercise limitation that prevents exercise to the extent ownership would exceed 4.99%.
The filing states neither reporting person has sole voting or dispositive power; voting and disposition are shared. Heights serves as investment manager to CVI and may exercise voting and dispositive power over the shares held by CVI, while each party disclaims beneficial ownership except for pecuniary interest.
Inmune Bio's Schedule 13G/A shows Praetorian-related entities holding disclosed positions in the company's common stock. Praetorian Capital Fund LLC directly beneficially owns 771,200 shares—comprised of 180,800 shares issuable upon warrants and 590,400 shares underlying call options exercisable within 60 days—representing approximately 2.9% of the class based on 26,585,258 shares outstanding. Mongolia (Barbados) Corp. directly owns 150,000 shares underlying call options (about 0.6%), and Harris Kupperman may be deemed to beneficially own a combined 921,200 shares (about 3.4%).
The filing identifies the reporting persons' roles (investment manager, manager, controlling person) and disclaims beneficial ownership beyond direct holdings. It specifies that reported positions include instruments exercisable within 60 days and includes a certification that the securities were not acquired to change or influence control of the issuer.
INmune Bio (NASDAQ:INMB) filed an 8-K announcing it will host a conference call on June 30, 2025 at 8:00 a.m. ET to present top-line data from its Phase 2 MINDFuL trial in early Alzheimer’s disease.
The filing:
- Attaches the related press release as Exhibit 99.1
- Provides no efficacy or safety figures; full results will be disclosed during the call
- Contains no changes to financial statements or guidance
The scheduling of a data read-out signals analysis completion and sets a near-term catalyst for shareholders, but the document itself does not alter the company’s financial position.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
